Research programme: metabolic disease therapeutics - European Lead Factory/Scandicure
Latest Information Update: 28 Feb 2023
At a glance
- Originator European Lead Factory; Scandicure AB
- Class Anti-inflammatories; Antihyperglycaemics; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Diabetes-mellitus in Europe
- 28 Feb 2023 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Europe